Document is current
Any future updates will be listed below
-
Authors
Kadivella, Mohammad https://orcid.org/0000-0003-3565-1543
Varma, Vivek P. https://orcid.org/0000-0003-4587-5719
CP, Jusail https://orcid.org/0000-0001-6666-4887
Kavela, Sridhar https://orcid.org/0000-0003-3676-4822
Azam, Sarwar https://orcid.org/0000-0001-7834-483X
Faisal, Syed M. https://orcid.org/0000-0002-8736-5170
-
Funding
Funding for this research was provided by:
Department of Biotechnology, Ministry of Science and Technology (BT/PR34488/MED/15/221/2022(SP094))
- License Information
-
More Information
Article History
Received: 8 January 2025
Accepted: 23 July 2025
First Online: 29 September 2025
Competing interests
: The authors declare no competing financial interests. A patent has been granted for NSF-951 and its formulation AF007, titled “Synthetic NSF-951 Agonist Compound and Preparation Thereof, Antigen-Alum-Synthetic NSF-951 Immuno-Formulation” (Patent No. 569943, dated 21 August 2025).
